Revenue
2019
2020
2022
2023
2024
2025
NextCure, Inc. (NXTC)
Price$7.82Cached quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | — | $22.4M | $6.3M | — |
| Research & development | $44.9M | $41.5M | $47.9M | $54.2M | $50.2M | $46.6M | $34.2M | $19.8M |
| Operating expenses | $57.6M | $59.7M | $67.6M | $75.9M | $70.8M | $63.6M | $43.8M | $23.2M |
| Operating income | −$57.6M | −$59.7M | −$67.6M | −$75.9M | −$70.8M | −$41.2M | −$37.5M | −$23.2M |
| Operating margin | — | — | — | — | — | −184.22% | −590.55% | — |
| EBITDA | −$55.4M | −$56.8M | −$63.9M | −$71.8M | −$66.5M | −$37.8M | −$34.8M | −$21.5M |
| EBITDA margin | — | — | — | — | — | −169.03% | −548.20% | — |
| Net income | −$55.8M | −$55.7M | −$62.7M | −$74.7M | −$69.4M | −$36.6M | −$33.7M | −$22.8M |
| Net profit margin | — | — | — | — | — | −163.57% | −531.54% | — |
| Basic EPSper basic share | -$19.65 | -$23.88 | -$337.50 | -$403.50 | -$376.50 | -$199.50 | -$322.50 | -$2,496.00 |
| Diluted EPSper diluted share | -$19.65 | -$23.88 | -$337.50 | -$403.50 | -$376.50 | -$199.50 | -$322.50 | -$2,496.00 |
Owners
Reported shareholders
≈8.32%of listed shares
Ren Jinsheng / Simcere Pharmaceutical Group Ltd / Hainan Simcere Zaiming Pharmaceutical Co., Ltd. / Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. / Tang Renhong / Simcere Zaiming, Inc.338.64K shares · Jun 20, 2025
View holders
| Holder | % owned |
|---|---|
Ren Jinsheng / Simcere Pharmaceutical Group Ltd / Hainan Simcere Zaiming Pharmaceutical Co., Ltd. / Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. / Tang Renhong / Simcere Zaiming, Inc. | ≈8.32%338.64K shares |
Ikarian Capital, LLC | 7.09%288.3K shares |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 6.81%277.2K shares |
Sofinnova Investments, Inc. | 5.47%222.65K shares |
RENAISSANCE TECHNOLOGIES LLC | 4.21%171.2K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.85%156.84K shares |
MILLENNIUM MANAGEMENT LLC | 2.17%88.11K shares |
BOOTHBAY FUND MANAGEMENT, LLC | 2.08%84.69K shares |
Squadron Capital Management LLC | 1.58%64.46K shares |
Verdad Advisers, LP | 1.49%60.45K shares |
Pfizer Inc | 1.09%44.35K shares |
Affinity Asset Advisors, LLC | 1.03%41.96K shares |
BlackRock, Inc. | 0.92%37.35K shares |
HRT FINANCIAL LP | 0.90%36.45K shares |
JANE STREET GROUP, LLC | 0.80%32.73K shares |
GEODE CAPITAL MANAGEMENT, LLC | 0.73%29.91K shares |
CARDIFF PARK ADVISORS, LLC | 0.54%21.83K shares |
ACADIAN ASSET MANAGEMENT LLC | 0.47%18.98K shares |
VANGUARD FIDUCIARY TRUST CO | 0.40%16.13K shares |
NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 0.31%12.5K shares |
Percentages use 4.07M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 3/A ↗Updated Sep 29, 2026 · Quarterly data